Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin — Stella

Home/Squamous Cell Carcinoma/

View on ClinicalTrials.gov

Recruiting

Back to Squamous Cell Carcinoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United States

Stanford University, Redwood City, California

Italy

Azienda Ospedliero-Universitaia, Bari

Key details

Phase

Safety & dosing

Sponsor

Stanford University

Collaborators

Epidermolysis Bullosa Research Partnership

Enrollment target

~16 participants

Started

March 2025

Primary completion

February 2027

Age range

18 Years and older

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.